Evidence map›Paper›PMID 42244674›Full record

ArticlebioRxiv : the preprint server for biology2026

GATA4 loss promotes mutant

Francesc Madriles, Monica P de Andres, Mikhail Chesnokov, Jaime Martinez de Villarreal, Direna Alonso-Curbelo, Natalia Del Pozo, Mar Iglesias, Enrique Carrillo-de-Santa-Pau, Juan Iovanna, Francisco Soriano and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Francesc MadrilesEpithelial Carcinogenesis Group, Tumor Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Monica P de AndresEpithelial Carcinogenesis Group, Tumor Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Mikhail ChesnokovEpithelial Carcinogenesis Group, Tumor Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Jaime Martinez de VillarrealEpithelial Carcinogenesis Group, Tumor Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Direna Alonso-CurbeloCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6674-3059
Natalia Del PozoEpithelial Carcinogenesis Group, Tumor Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Mar IglesiasDepartment of Pathology, Parc de Salut Mar, Barcelona, Spain.
Enrique Carrillo-de-Santa-PauEpithelial Carcinogenesis Group, Tumor Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Juan IovannaCentre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
Francisco SorianoEpithelial Carcinogenesis Group, Tumor Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Ana CuadradoChromosome Dynamics Group, Molecular Oncology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Miriam MarquesEpithelial Carcinogenesis Group, Tumor Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Javier MuñozProteomics Unit, Biotechnology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Irene EspositoInstitute of Pathology, Heinrich-Heine University & University Hospital, Duesseldorf, Germany.
Paola MartinelliEpithelial Carcinogenesis Group, Tumor Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Scott W LoweCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Francisco X RealEpithelial Carcinogenesis Group, Tumor Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.

Funding

Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic TumorigenesisR01CA283378 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCOTT W. LOWE, Dana Pe'er · 2023 to 2026
$2.9M
NCI NIH HHS R01 CA283378
6 · The paper itself

Abstract

GATA6 and GATA4 play key roles in pancreatic development and are essential to maintain the classical transcriptional program in pancreatic ductal adenocarcinoma (PDAC). Using genetic mouse models we show that, in contrast to GATA6, GATA4 is dispensable for the maintenance of acinar homeostasis in the adult pancreas. Deletion of

Identifiers

PMID42244674
PMCPMC13232281

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.